POM-V Prescription Required Companion Animal

Metrovis 100 mg Tablets for Dogs and Cats

Active ingredient: Metronidazole

Form

Tablet

Species

Cats Dogs

Manufacturer

Industrial Veterinaria SA

VMD MA No.

36547/3019

What it's used for

Treatment of gastrointestinal tract infections caused by spp. and spp. (i.e. C. perfringens or ). Treatment of infections of the urogenital tract, oral cav...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Metronidazole

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Metrovis 100 mg Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Treatment of gastrointestinal tract infections caused by spp. and
spp. (i.e. C. perfringens or ).
Treatment of infections of the urogenital tract, oral cavity, throat, and skin caused by
obligate anaerobic bacteria (e.g. Clostridia spp.) susceptible to metronidazole.

For oral use.
The recommended dose is 50 mg metronidazole per kg bodyweight per day, for 5-7
days. The daily dose may be split into two administrations per day (i.e. 25
mg/kg bodyweight twice daily).
To ensure administration of the correct dosage, bodyweight should be determined as
accurately as possible. The following table is intended as a guide to dispensing the
product at the recommended dose rate of either 50 mg per kg bodyweight,
administered once daily or, preferably, administered twice daily in 25 mg per kg
bodyweight.
Number of tabletsTwice daily
Bodyweight
(kg)
MorningEvening
Once daily
0.5 kg¼-¼1 kg¼¼½2 kg½½13 kg¾¾1 ½4 kg1125 kg1 ¼1 ¼2 ½6 kg1 ½1 ½37 kg1 ¾1 ¾3 ½8 kg224
= ¼ tablet = ½ tablet = ¾ tablet = 1 tablet
Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the
tablet on a flat surface, with its scored side facing up and the convex (rounded) side
facing the surface.
Halves: press down with your thumbs on both sides of the tablet.
Quarters: press down with your thumb in the middle of the tablet.

Revised: November 2025
AN: 02603/2025Page 4 of 6

Do not use in case of hepatic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.

The following adverse reactions may occur after administration of metronidazole:
vomiting, hepatotoxicity, neutropenia and neurological signs.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

None.

Special precautions for use in animals
Due to the likely variability (time, geographical) in the occurrence of metronidazole
resistant bacteria, bacteriological sampling and susceptibility testing are
recommended.

Revised: November 2025
AN: 02603/2025Page 2 of 6
Whenever possible, the product should only be used based on susceptibility testing.
Official, national and regional antimicrobial policies should be taken into account
when the veterinary medicinal product is used.
In very rare cases, neurological signs may occur especially after prolonged treatment
with metronidazole.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Metronidazole has confirmed mutagenic and genotoxic properties in laboratory
animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory
animals and has possible carcinogenic effects in humans. However, there is
inadequate evidence in humans for the carcinogenicity of metronidazole.
Metronidazole may be harmful for the unborn child.
Impervious gloves should be worn during administration of the product to avoid skin
contact with the product.
To avoid accidental ingestion, particularly by a child, unused tablets and part-tablets
should be returned to the open blister space, inserted back into the outer packaging
and kept in a safe place out of the sight and reach of children. In case of accidental
ingestion, seek medical advice immediately and show the package leaflet or the label
to the physician. Wash hands thoroughly after handling the tablets.
Metronidazole may cause hypersensitivity reactions. In case of known
hypersensitivity to metronidazole, avoid contact with the veterinary medicinal product.

Metronidazole may have an inhibitory effect on the degradation of other drugs in the
liver, such as phenytoin, cyclosporine and warfarin.

Revised: November 2025
AN: 02603/2025Page 3 of 6
Cimetidine may decrease the hepatic metabolism of metronidazole resulting in
increased serum concentration of metronidazole.
Phenobarbital may increase hepatic metabolism of metronidazole resulting in
decreased serum concentration of metronidazole.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.